SEARCH

SEARCH BY CITATION

References

  • 1
    Hundsberger H, Verin A, Wiesner C et al. TNF: a moonlighting protein at the interface between cancer and infection. Front Biosci 2008; 13: 537486.
  • 2
    Creasey AA, Reynolds MT, Laird W. Cures and partial regression of murine and human tumors by recombinant human tumor necrosis factor. Cancer Res 1986; 46: 568790.
  • 3
    Sugarman BJ, Aggarwal BB, Hass PE, Figari IS, Palladino MA Jr, Shepard HM. Recombinant human tumor necrosis factor-alpha: effects on proliferation of normal and transformed cells in vitro. Science 1985; 230: 9435.
  • 4
    Locksley RM, Killeen N, Lenardo MJ. The TNF and TNF receptor superfamilies: integrating mammalian biology. Cell 2001; 104: 487501.
  • 5
    Tracey KJ, Lowry SF, Cerami A. The pathophysiologic role of cachectin/TNF in septic shock and cachexia. Ann Inst Pasteur Immunol 1988; 139: 3117.
  • 6
    Lin WJ, Yeh WC. Implication of Toll-like receptor and tumor necrosis factor alpha signaling in septic shock. Shock 2005; 24: 2069.
  • 7
    Abbruzzese JL, Levin B, Ajani JA et al. Phase I trial of recombinant human gamma-interferon and recombinant human tumor necrosis factor in patients with advanced gastrointestinal cancer. Cancer Res 1989; 49: 405761.
  • 8
    Blick M, Sherwin SA, Rosenblum M, Gutterman J. Phase I study of recombinant tumor necrosis factor in cancer patients. Cancer Res 1987; 47: 29869.
  • 9
    De Blasi RA, Palmisani S, Alampi D et al. Microvascular dysfunction and skeletal muscle oxygenation assessed by phase-modulation near-infrared spectroscopy in patients with septic shock. Intensive Care Med 2005; 31: 16618.
  • 10
    Lejeune FJ, Liénard D, Matter M, Rüegg C. Efficiency of recombinant human TNF in human cancer therapy. Cancer Immun 2006; 6: 6.
  • 11
    Lienard D, Ewalenko P, Delmotte JJ, Renard N, Lejeune FJ. High-dose recombinant tumor necrosis factor alpha in combination with interferon gamma and melphalan in isolation perfusion of the limbs for melanoma and sarcoma. J Clin Oncol 1992; 10: 5260.
  • 12
    Koops HS, Garbe C, Hohenberger P. Is isolated limb perfusion of metastatic malignant melanoma of the extremity worthwhile? Eur J Cancer 1996; 32A: 163340.
  • 13
    Hohenberger P, Haier J, Schlag PM. Rhabdomyolysis and renal function impairment after isolated limb perfusion – comparison between the effects of perfusion with rhTNF alpha and a ‘triple-drug’ regimen. Eur J Cancer 1997; 33: 596601.
  • 14
    Allen RE Jr. Systemic leakage and side effects of tumor necrosis factor alpha administration via isolated limb perfusion can be manipulated by flow rate adjustment. Arch Surg 1996; 131: 220.
  • 15
    Varfolomeev E, Blankenship JW, Wayson SM et al. IAP antagonists induce autoubiquitination of c-IAPs, NF-kappaB activation, and TNFalpha-dependent apoptosis. Cell 2007; 131: 66981.
  • 16
    Gerspach J, Németh J, Münkel S, Wajant H, Pfizenmaier K. Target-selective activation of a TNF prodrug by urokinase-type plasminogen activator (uPA) mediated proteolytic processing at the cell surface. Cancer Immunol Immunother 2006; 55: 1590600.
  • 17
    Gregorc V, Santoro A, Bennicelli E et al. Phase Ib study of NGR-hTNF, a selective vascular targeting agent, administered at low doses in combination with doxorubicin to patients with advanced solid tumours. Br J Cancer 2009; 101: 21924.
  • 18
    Wang H, Chen K, Cai W et al. Integrin-targeted imaging and therapy with RGD4C-TNF fusion protein. Mol Cancer Ther 2008; 7: 104453.
  • 19
    Yan Z, Zhao N, Wang Z et al. A mutated human tumor necrosis factor-alpha improves the therapeutic index in vitro and in vivo. Cytotherapy 2006; 8: 41523.
  • 20
    Li M, Qin X, Xue X et al. Safety evaluation and pharmacokinetics of a novel human tumor necrosis factor-alpha exhibited a higher antitumor activity and a lower systemic toxicity. Anticancer Drugs 2010; 21: 24351.
  • 21
    Pocock SJ, Simon R. Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial. Biometrics 1975; 31: 10315.
  • 22
    Creasey AA, Doyle LV, Reynolds MT, Jung T, Lin LS, Vitt CR. Biological effects of recombinant human tumor necrosis factor and its novel muteins on tumor and normal cell lines. Cancer Res 1987; 47: 1459.
  • 23
    Soma G, Kitahara N, Tsuji Y et al. Improvement of cytotoxicity of tumor necrosis factor (TNF) by increase in basicity of its N-terminal region. Biochem Biophys Res Commun 1987; 148: 62935.
  • 24
    Kamijo R, Takeda K, Nagumo M et al. Induction of differentiation of human monoblastic and myeloblastic leukemia cell lines by TNF muteins. Biochem Biophys Res Commun 1989; 160: 8207.
  • 25
    Seynhaeve AL, Eggermont AM, ten Hagen TL. TNF and manipulation of the tumor cell-stromal interface: “ways to make chemotherapy effective”. Front Biosci 2008; 13: 303445.
  • 26
    Petrache I, Birukova A, Ramirez SI, Garcia JG, Verin AD. The role of the microtubules in tumor necrosis factor-alpha-induced endothelial cell permeability. Am J Respir Cell Mol Biol 2003; 28: 57481.
  • 27
    Santoro A, Rimassa L, Sobrero AF et al. Phase II study of NGR-hTNF, a selective vascular targeting agent, in patients with metastatic colorectal cancer after failure of standard therapy. Eur J Cancer 2010; 46: 274652.
  • 28
    Furman WL, Strother D, McClain K, Bell B, Leventhal B, Pratt CB. Phase I clinical trial of recombinant human tumor necrosis factor in children with refractory solid tumors: a Pediatric Oncology Group study. J Clin Oncol 1993; 11: 220510.
  • 29
    Starnes CO. Coley’s toxins in perspective. Nature 1992; 357: 112.